Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Q4 2025 value amounting to $277000.0.

  • Arrowhead Pharmaceuticals' Other Non Operating Income fell 1876.83% to $277000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $5.2 million, marking a year-over-year increase of 38419.04%. This contributed to the annual value of $5.3 million for FY2025, which is 40085.81% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Other Non Operating Income of $277000.0 as of Q4 2025, which was down 1876.83% from $4.7 million recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Other Non Operating Income registered a high of $4.7 million during Q3 2025, and its lowest value of -$3.1 million during Q3 2024.
  • In the last 5 years, Arrowhead Pharmaceuticals' Other Non Operating Income had a median value of $323500.0 in 2023 and averaged $350400.0.
  • Examining YoY changes over the last 5 years, Arrowhead Pharmaceuticals' Other Non Operating Income showed a top increase of 226250.0% in 2024 and a maximum decrease of 53486.75% in 2024.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Other Non Operating Income (Quarter) stood at -$707000.0 in 2021, then surged by 171.71% to $507000.0 in 2022, then decreased by 16.96% to $421000.0 in 2023, then fell by 19.0% to $341000.0 in 2024, then decreased by 18.77% to $277000.0 in 2025.
  • Its last three reported values are $277000.0 in Q4 2025, $4.7 million for Q3 2025, and -$176000.0 during Q2 2025.